title: [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease].
abstract: BACKGROUND
  Some studies have shown that CSF amyloid-beta 1-42 (Aβ₁₋₄₂), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau(181p)) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheimeŕs disease (AD). Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture.
  
  
  METHODS
  A total of 36 MCI patients were included from the local hospital memory clinic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we measured CSF Aβ₁₋₄₂, T-tau and P-tau(181p) proteins, and calculated the T-tau/Aβ₁₋₄₂ y P-tau(181p)/Aβ₁₋₄₂ ratios. This project was approved by the local ethics committee.
  
  
  RESULTS
  One year after the lumbar puncture, 14 MCI patients (38%) developed AD. These patients had lower Aβ₁₋₄₂ protein levels (285.3 vs 377 ng/ml, P<.02) and higher P-tau(181p)/Aβ₁₋₄₂ ratio (0,25 vs 0,16, p<.02) than the clinically stable patients.
  
  
  CONCLUSIONS
  Our MCI patients with lower Aβ₁₋₄₂ protein levels and an increased P-tau(181p) /Aβ₁₋₄₂ ratio progressed quickly to AD. These results may help to identify those MCI patients with a poorer prognosis.
authors.affiliation: Servicio de Neurología, Hospital General Universitario de Alicante, Alicante, España. monge jos@gva.es
authors.forename: J A
authors.initials: JA
authors.lastname: Monge-Argilés
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Payá
authors.forename: C
authors.initials: C
authors.lastname: Muñoz-Ruiz
authors.forename: A
authors.initials: A
authors.lastname: Pampliega-Pérez
authors.forename: M J
authors.initials: MJ
authors.lastname: Gómez-López
authors.forename: E
authors.initials: E
authors.lastname: Rodríguez Borja
authors.forename: J
authors.initials: J
authors.lastname: Montoya-Gutiérrez
authors.forename: C
authors.initials: C
authors.lastname: Leiva-Santana
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000209:etiology*; D000647:Amnesia / Q000209:etiology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D060825:Cognitive Dysfunction / Q000134:cerebrospinal fluid* / Q000150:complications*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D007118:Immunoassay; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D011379:Prognosis; D012372:ROC Curve; D015203:Reproducibility of Results; D013129:Spinal Puncture; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins